CytomX Therapeutics (NASDAQ:CTMX) Price Target Raised to $10.00 at Cantor Fitzgerald

CytomX Therapeutics (NASDAQ:CTMX) had its target price upped by analysts at Cantor Fitzgerald from $6.00 to $10.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage currently has an “overweight” rating on the biotechnology company’s stock. Cantor Fitzgerald’s price target suggests a potential upside of 74.61% from the company’s current price.

Several other research analysts have also weighed in on CTMX. Wall Street Zen lowered CytomX Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Piper Sandler raised their price target on shares of CytomX Therapeutics from $6.50 to $10.00 and gave the company an “overweight” rating in a research report on Tuesday, January 20th. Wedbush reiterated an “outperform” rating and issued a $6.00 price objective on shares of CytomX Therapeutics in a research note on Friday, November 7th. HC Wainwright increased their target price on CytomX Therapeutics from $5.00 to $10.00 and gave the company a “buy” rating in a report on Tuesday, November 11th. Finally, Weiss Ratings upgraded CytomX Therapeutics from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, October 8th. Seven research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, CytomX Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $9.00.

CytomX Therapeutics Price Performance

NASDAQ:CTMX traded down $0.34 during mid-day trading on Wednesday, hitting $5.73. The company’s stock had a trading volume of 830,541 shares, compared to its average volume of 3,240,263. CytomX Therapeutics has a 1 year low of $0.40 and a 1 year high of $6.35. The stock has a market cap of $970.33 million, a price-to-earnings ratio of 14.51 and a beta of 2.44. The business’s fifty day moving average is $4.55 and its two-hundred day moving average is $3.43.

CytomX Therapeutics (NASDAQ:CTMX) last announced its earnings results on Thursday, November 6th. The biotechnology company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.05). CytomX Therapeutics had a return on equity of 44.49% and a net margin of 24.66%.The business had revenue of $5.96 million for the quarter, compared to analyst estimates of $11.50 million. Analysts anticipate that CytomX Therapeutics will post -0.05 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. Orbimed Advisors LLC bought a new stake in CytomX Therapeutics during the second quarter valued at $19,208,000. Commodore Capital LP acquired a new stake in shares of CytomX Therapeutics during the 2nd quarter worth approximately $17,462,000. Perceptive Advisors LLC acquired a new position in CytomX Therapeutics during the 2nd quarter valued at approximately $15,876,000. Vivo Capital LLC bought a new position in CytomX Therapeutics during the 2nd quarter worth $13,096,000. Finally, Franklin Resources Inc. acquired a new stake in CytomX Therapeutics in the second quarter worth $13,096,000. Institutional investors own 67.77% of the company’s stock.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.